8-KLeadership ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Jan 14, 2014)

Filed January 14, 2014For Securities:DGX

Summary

This 8-K filing from Quest Diagnostics Incorporated (DGX) on January 14, 2014, primarily reports a change in the composition of its Board of Directors. Effective January 10, 2014, the Board expanded its size from nine to ten members and elected Timothy L. Main as a new director. Mr. Main, who is the Chairman of Jabil Circuit, Inc., has been deemed an independent director and was appointed to the Audit and Finance Committee. This board expansion and appointment could indicate a strategic move by Quest Diagnostics to strengthen its governance and potentially bring in new expertise. Investors should note that Mr. Main's compensation as a non-employee director will follow the company's standard practices, including a stock option and restricted stock unit grant. The filing also references a press release from January 13, 2014, which provides further details on this director appointment.

Key Highlights

  • 1Quest Diagnostics Board of Directors increased in size from 9 to 10 members.
  • 2Timothy L. Main elected as a new director.
  • 3Timothy L. Main is Chairman of Jabil Circuit, Inc.
  • 4Mr. Main has been determined to be an independent director.
  • 5Mr. Main appointed to the Audit and Finance Committee, expanding it to 5 members.
  • 6New director compensation includes a one-time grant of 2,037 stock options and 658 restricted stock units.
  • 7A press release dated January 13, 2014, announcing the election is attached as an exhibit.

Frequently Asked Questions

The filing states the Board's size was increased from 9 to 10 directors. While the specific strategic reasons are not detailed in this 8-K, such expansions often occur to bring in new expertise, refresh perspectives, or accommodate growth and evolving business needs. Investors may infer a focus on strengthening board oversight or governance.

Timothy L. Main is the Chairman of Jabil Circuit, Inc. He has been elected as an independent director to Quest Diagnostics' Board and appointed to its Audit and Finance Committee. His role as Chairman of another public company suggests significant experience in corporate leadership and potentially financial oversight.

Mr. Main will receive compensation as a non-employee director in accordance with Quest Diagnostics' established practices, as outlined in their proxy statement. As part of this, he received a one-time grant of 2,037 stock options and 658 restricted stock units upon joining the Board.

His appointment to the Audit and Finance Committee, which was also expanded, suggests an emphasis on financial oversight and governance. This committee typically plays a crucial role in reviewing financial reporting, internal controls, and risk management, indicating a focus on these areas for Quest Diagnostics.